Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial

Overview of attention for article published in Frontiers in endocrinology, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

blogs: 1 blog

twitter: 4 X users

Readers on

mendeley: 43 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 6,152 followers.

New NUTRITION Research Available. Click Here to Access Article(s): https://t.co/AZZ9DGrI0X

New Research: Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial: Background Understanding which group of patients with type 2 diabetes will have… https://t.co/lYYyl6K…

RT @RinkiMurphy: Pioglitazone produces more glucose lowering than vildagliptin in NZers with T2D who also have obesity and/or hypertriglyce…

Pioglitazone produces more glucose lowering than vildagliptin in NZers with T2D who also have obesity and/or hypertriglyceridemia. Māori and/or Pacific ethnicity is not a sufficient proxy for predicting this stratified medicine response. ⁦@MWC_CoRE⁩ http…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.